Your session is about to expire
← Back to Search
Neoantigen Vaccine + Pembrolizumab for Follicular Lymphoma
Study Summary
This trial is studying a new type of FL vaccine which may be a treatment for follicular lymphoma. The agents used in this study are Rituximab, a personalized NeoAntigen vaccine, Poly-ICLC, and Pembrolizumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV-positive and may be on antiretroviral therapy.I agree to provide samples of my tumor and normal tissues for testing.My lymphoma has changed into a more aggressive type.I have had a bone marrow or stem cell transplant.I am not taking any drugs that affect my immune system.I haven't had any vaccines other than for cancer in the last 2 weeks.I have not had systemic therapy for follicular lymphoma, but may have had radiation over 3 months ago.I need regular IVIG treatments.I do not have an active hepatitis B or C infection.I do not have any unmanaged ongoing illnesses.My lymphoma is grade I-IIIA and confirmed by DFCI/BWH.I am scheduled for 4 weekly doses of rituximab.I am 18 years old or older.I can do most of my daily activities without help.My blood tests for organ function and blood cell counts are normal.My cancer has not improved or remains large after treatment with rituximab.I have had cancer before, but it's one of the exceptions.I have recovered from side effects of rituximab, except for mild neuropathy.I have received radiation for treatment within the last 3 months.I have had treatment for follicular lymphoma, but only rituximab.My cancer has spread to my brain or spinal cord.I have received treatment with specific medications before.
- Group 1: Neo Vax
- Group 2: NeoVax and pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there vacancies in this experiment open to participants?
"Affirmative, clinicaltrials.gov states that this clinical trial is in the process of recruiting patients. The research was initially published on March 14th 2022 and recently updated with new information. 20 participants are needed between 1 medical centre for the study to progress further."
What is the aggregate enrollment of this trial?
"Affirmative, the information on clinicaltrials.gov declares that this examination is actively enrolling patients. This research project was initially uploaded to the website on March 14th of 2022 and most recently updated around the same date. 20 volunteers are needed from a single site."
What potential health hazards are associated with Neo Vax?
"Due to the limited evidence of efficacy and safety, the Power research team has given Neo Vax a score of 1 on their risk scale."
What other experiments involving Neo Vax have been undertaken in the past?
"As of now, 1357 Neo Vax trials are active with 214 reaching Phase 3. Most notably, numerous medical centres in Houston, Texas are participating in the clinical trial process for this drug but there are 49950 facilities across the world conducting clinical studies on it as well."
To what illnesses does Neo Vax typically offer relief?
"Neo Vax is the go-to solution for treating polyangium and can also be beneficial in addressing malignant neoplasms, unresectable melanoma, as well as microsatellite instability high."
Share this study with friends
Copy Link
Messenger